BORA PHARMACEUTICALS LTD Cash Flow Conversion Efficiency
BORA PHARMACEUTICALS LTD cash flow conversion efficiency. Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) has a cash flow conversion efficiency ratio of 0.034x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$568.46 Million ≈ $17.91 Million USD) by net assets (NT$16.63 Billion ≈ $523.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BORA PHARMACEUTICALS LTD (2019–2025)
Cash flow conversion efficiency of BORA PHARMACEUTICALS LTD from 2019 to 2025. This chart illustrates how BORA PHARMACEUTICALS LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 6472 share price today for real-time trading data and today's change.
BORA PHARMACEUTICALS LTD Cash Flow Conversion Ratio Explained
BORA PHARMACEUTICALS LTD cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BORA PHARMACEUTICALS LTD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BORA PHARMACEUTICALS LTD ranked by their cash flow conversion efficiency. Also see 6472 market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu New Energy Development Co Ltd
SHG:603693
|
0.063x |
|
agilon health Inc
NYSE:AGL
|
-0.148x |
|
Farglory Land Development Co Ltd
TW:5522
|
0.056x |
|
IBI Inv House
TA:IBI
|
0.094x |
|
Galecto Inc
NASDAQ:GLTO
|
-0.040x |
|
Shaily Engineering Plastics Limited
NSE:SHAILY
|
0.137x |
|
Ganfeng Lithium Co. Ltd
F:39EA
|
0.025x |
|
SASA Polyester Sanayi AS
IS:SASA
|
0.052x |
Annual Cash Flow Conversion Efficiency for BORA PHARMACEUTICALS LTD (2019–2025)
The table below shows the annual cash flow conversion efficiency of BORA PHARMACEUTICALS LTD from 2019 to 2025. Review 6472 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | NT$17.47 Billion ≈ $550.47 Million |
NT$4.24 Billion ≈ $133.64 Million |
0.243x | +271.59% |
| 2024-09-30 | NT$15.01 Billion ≈ $472.95 Million |
NT$980.81 Million ≈ $30.90 Million |
0.065x | -83.34% |
| 2023-09-30 | NT$11.77 Billion ≈ $370.69 Million |
NT$4.61 Billion ≈ $145.36 Million |
0.392x | +0.28% |
| 2022-09-30 | NT$5.14 Billion ≈ $161.95 Million |
NT$2.01 Billion ≈ $63.33 Million |
0.391x | -0.32% |
| 2021-09-30 | NT$3.15 Billion ≈ $99.32 Million |
NT$1.24 Billion ≈ $38.96 Million |
0.392x | +443.81% |
| 2020-09-30 | NT$2.46 Billion ≈ $77.65 Million |
NT$177.79 Million ≈ $5.60 Million |
0.072x | -48.53% |
| 2019-09-30 | NT$1.65 Billion ≈ $52.10 Million |
NT$231.77 Million ≈ $7.30 Million |
0.140x | -- |
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more